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Background: Depression is common in heart failure (HF), but there is little data on the 
characteristics of antidepressant use in patients with HF.
Objective: To survey basic information on antidepressant prescription characteristics, use, 
effectiveness, and follow-up.
Methods: Observational study in two outpatient cardiology clinics of 37 NYHA class I–IV 
HF patients taking antidepressant medication.
Results: Thirty-one percent of prescriptions for antidepressants were obtained from psychiatrists, 
58% from primary care physicians, and 8% from cardiologists. The majority of patients (87%) 
reported regularly taking their antidepressant medication as prescribed, however 48% reported 
never having had the dosage of their antidepressant medication adjusted. Only 53% of the 
patients reported that the medication had helped their mood “almost entirely” or “mostly” back 
to normal since starting their antidepressants, while the remaining patients reported that their 
mood was only “halfway” or “somewhat” back to normal or that the medication had not helped 
their depression at all. Among a subset of 10 patients who completed the Beck Depression (BDI) 
inventory, 6 still had depressed mood (BDI  10).
Conclusion: The ﬁ  ndings from this survey study provide insight into the characteristics of 
antidepressant use in patients with HF and argue for better follow up of HF patients who are 
prescribed antidepressants.
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Introduction
Among patients with chronic illness, comorbid depression (depression superimposed 
on chronic illness) incrementally worsens health and quality of life (Moussavi et al 
2007). Increasing attention is being paid to the high rates of comorbid depression in 
patients with HF (Rutledge et al 2006). In patients with HF, comorbid depression is 
present in up to 42% of cases and is associated with increased morbidity and mortality 
(Jiang et al 2001; Norra et al 2008).
Historically, few depressed HF patients received antidepressant treatment, although 
this has begun to change (Jacob et al 2003; Norra et al 2008). Although the efﬁ  cacy 
of treating depression in ultimately altering cardiac related outcomes in HF is not 
established (Shapiro 2007), recent studies do suggest that treatment with certain 
antidepressants – including selective serotonin reuptake inhibitors (SSRI’s) and 
tricyclics – might help reduce clinically relevant underlying inﬂ  ammatory processes 
in HF (Tousoulis et al 2008).
What is missing from the literature is information about the characteristics of antide-
pressant use in HF. A number of clinically relevant questions are currently unanswered 
that could help guide future intervention efforts. For example, among HF patients 
receiving antidepressants, when did their depression begin in relation to their HF 
diagnosis? From whom did they receive the medication treatment? How aggressively Patient Preference and Adherence 2008:2 334
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was their antidepressant treatment followed and adjusted? 
And how efﬁ  cacious was the treatment in the course of 
routine clinical practice? While it is known that adherence 
to HF medication is often poor in these patients (Hauptman 
2008), and that this may be partially explained by the presence 
of depression in some patients (Morgan et al 2006), there is 
little published information on adherence to antidepressants 
in depressed HF patients.
In response to the scarcity of information in the literature, 
we developed a brief questionnaire as a method for gathering 
information on antidepressants and their use in patients with 
HF. In this brief report, we offer preliminary ﬁ  ndings in this 
regard.
Methods
Thirty-seven stable NYHA class I–IV HF patients (age range 
30 to 90 years) were studied. Participants were recruited 
from either the UCSD Heart Failure Program or the Veterans 
Affairs Medical Center Coronary Care Program. This study 
on antidepressant medication, which is part of a larger 
ongoing project on depression in HF, was approved by the 
University of California, San Diego Institutional Review 
Board. All subjects gave informed written consent.
Outpatients were approached at the clinics and asked if 
they were taking antidepressant medication and, if so, would 
they be willing to complete a brief questionnaire about their 
history and experiences with depression and antidepres-
sants. Patients were told that their results would be kept 
conﬁ  dential. Approximately 45 patients were approached 
to participate.
The 22 item questionnaire was developed by a team 
of psychologists and psychiatrists who are experienced 
with mental health factors in HF populations. Primary 
information sought in the questionnaire included: 1) who 
had prescribed their antidepressant (Psychiatrist, Primary 
Care Physician, Cardiologist, Other), 2) whether they were 
formally diagnosed with depression before receiving their 
antidepressant, 3) how long they had been feeling blue 
or depressed before receiving antidepressant treatment, 
4) whether their symptoms of depression appeared before 
or after receiving their HF diagnosis, 5) their current anti-
depressant medication and dosage, 6) whether they had 
any dosage adjustments of their antidepressant medication, 
7) whether they took their antidepressant regularly and at 
the prescribed dosage (and if not, why not), 8) whether 
the antidepressant had improved their mood (entirely or 
almost entirely back to normal, mostly back to normal, 
halfway back to normal, or somewhat back to normal, 
or no improvement), and 9) whether they were currently 
participating in adjunctive psychotherapy or behavioural 
therapy.
Answers from the questionnaire were analyzed descrip-
tively and by chi-square tests where appropriate.
Results
Characteristics of the 37 patients who agreed to participate 
are presented in Table 1. Fifty-ﬁ  ve percent of the patients 
reported that they had depressive symptoms prior to receiving 
their HF diagnosis. Only 43% of the patients reported that 
they had been formally diagnosed with depression prior to 
receiving antidepressant medication. Patients reported that 
they had been “feeling depressed or blue” for an average of 
7.5 years (SD = 10.2) before receiving treatment.
Thirty-one percent of patients reported that they received 
their antidepressants through a psychiatrist. Another 58% 
reported that they received their antidepressants through their 
primary care physician, while three patients (8%) reported 
receiving their antidepressant through his/her cardiologist.
The majority of patients (78%) were on SSRI’s (paroxetine, 
ﬂ  uoxetine, citalopram, escitalopram, sertraline), with other 
medications including imipramine, mirtazapine, chlordiaz-
epoxide and bupropion. Types of medications prescribed by 
psychiatrists versus primary care physicians did not differ sig-
niﬁ  cantly. Medication dosages provided by the patients were 
in line with standard prescriptions for these compounds.
Since receiving their prescription, nearly half (48%) of the 
patients reported that they never had the dosage of their antide-
pressant medication adjusted. Eighty-seven percent reported 
that they regularly took their medication as prescribed. 
Seventy-three percent of patients receiving their medications 
from a psychiatrist had their dosages adjusted at least once, 
while only 42% of patients receiving their medications from 
a primary care physician had their dosages adjusted at least 
once (this difference was not statistically signiﬁ  cant).
As far as effects of the antidepressants on mood, 
only 53.3% of the patients reported that the medication 
Table 1 Sample characteristics (mean ± SD)
Sample size 37
Age (years) 61.6 (± 35)
Gender 29 men; 8 women
NYHA Class (available on 34 
of the 37 patients)
I – 8
II – 14
III – 7
IV – 5
Ejection fraction (%)   40.8 (± 12)Patient Preference and Adherence 2008:2 335
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had helped their mood to get “almost entirely” or “mostly” 
back to normal, while 36.6% reported that their mood was 
only “halfway” or “somewhat” back to normal, and 10% 
reported that the medication had not helped their mood at 
all (Figure 1). There were no differences in reported mood 
between patients who had their depressive symptoms prior 
to versus after receiving their HF diagnosis, or between those 
who had versus never had their dosage adjusted.
At the time of completing the 22-item questionnaire, as 
part of another larger study, 10 of the patients also completed 
the Beck Depression Inventory (BDI) (Beck et al 1996). 
Six of these patients still had elevated depressive mood 
(BDI  10) (mean score 16.4; range 10 to 34) and 4 of those 
could be considered clinically depressed (BDI  17) (mean 
score 26.7, range 17 to 34).
Twenty percent of the patients reported currently partici-
pating in adjunctive/behavioral therapy.
Discussion
Depression remains a highly important topic in HF. Preva-
lence rates of clinically signiﬁ  cant depression in HF range 
from 11% to 42% among New York Heart Association 
classes I versus IV, respectively, with overall estimates 
of approximately 30% (Rutledge et al 2006; Norra et al 
2008). Recent reviews of the HF literature demonstrate that 
comorbidity with depression is associated with increased 
healthcare utilization, functional disability, and a poorer 
medical prognosis (Rutledge et al 2006; Egede 2007).
It is known that only a small percentage of HF patients 
with comorbid depression receive antidepressant medica-
tion (Norra et al 2008). Our study was not designed to 
provide an estimate of prevalence of antidepressant usage, 
but rather information about patients who have received 
such medication. We are unaware of any study to date 
that has described characteristics of antidepressant use 
among HF patients being treated for depression. Although 
adherence to HF medication is reported as often poor in 
patients with HF (Hauptman 2008), the majority (87%) in 
our sample reported that they regularly took their antide-
pressant medication as prescribed, although only roughly 
half reported that their mood had returned to normal or 
near normal.
Only three of the patients reported receiving antidepressant 
medication from their cardiologist, with the remainder receiving 
them from a psychiatrist or primary care physician. The major-
ity of patients were on selective serotonin reuptake inhibitors, 
which are considered effective therapy for HF patients with 
depression (Parissis et al 2007; Serebruany et al 2003).
Recent studies ﬁ  nd that among HF patients at different 
stages of their illness, changes over time in depression 
symptoms are important to clinical outcomes (Koenig 
et al 2006; Azevedo et al 2008). Among the important 
findings from this survey include that depressed HF 
patients on antidepressant medication are not being rou-
tinely followed to optimize therapy. Half of the patients 
in this study reported never having had the dosage of 
Almost entirely back to normal
23.3
Mostly back to normal
30
Halfway back to normal
20 Somewhat back to normal
16.6
No improvement in mood
10
Figure 1 The ﬁ  gure presents the respective percentages of patients providing one of ﬁ  ve possible responses to the question, “Do you think the antidepressant medication has 
improved your mood?” Patients could respond with either my mood is ‘Almost entirely back to normal’, ‘Mostly back to normal’, ‘Halfway back to normal’, ‘Somewhat back to 
normal’, or ‘No improvement’. Only slightly more than half of the patients (53.3%) reported a signiﬁ  cant improvement in their depression.Patient Preference and Adherence 2008:2 336
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their antidepressant medication adjusted and a signiﬁ  cant 
percentage self reported that their mood was not back to 
normal (Adams et al 2008). A partial response to anti-
depressant treatment is known to be a strong predictor 
of depression relapse (Furukawa et al 2007). Among the 
subset of patients on antidepressants who completed the 
BDI, 60% still had depressed mood, which is consis-
tent with the reports from the larger cohort of roughly 
46% reporting that their mood had not returned to normal 
or mostly normal.
We designed this questionnaire in response to what we 
perceived as gaps in the literature on HF and antidepres-
sant use. We do not know the degree to which our ﬁ  ndings 
might generalize to other HF patients taking antidepres-
sants or how the ﬁ  ndings in this sample might differ from 
those patients at our clinics who refused to participate 
in this study. Approximately 85% of those patients 
approached were willing to complete the questionnaire, 
which is a considerably higher percentage compared to a 
49% willingness to participate rate in a study of attitudes 
about impairment in HF patients prescreened for depression 
(Turvey et al 2006).
The modest sample size is a limitation of this study. 
This is an ongoing project, however, and it is our intention 
to expand the sample size and scope of this particular line 
of research. In addition, we did not gather information on 
family history of depression, which does have a bearing on 
depression treatment and clinical course in HF (Artinian et al 
2004; Koenig et al 2006).
In summary, these ﬁ  ndings provide some preliminary 
insight into the characteristics of antidepressant use 
in patients with HF. Despite receiving antidepressant 
treatment, results from our sample suggest that many 
HF patients are inadequately treated and continue to expe-
rience depressed mood and may be vulnerable to relapse 
or progression of their depression, particularly as their 
HF advances. Similarly, the aggressiveness of treatment 
follow-up and dosage adjustments for antidepressant therapy 
are less than optimal for achieving long term improvement in 
depressive symptoms. Although the importance of treating 
depression in HF is receiving increasing recognition (Blier 
et al 2007; Shapiro 2007), our ﬁ  ndings indicate that attention 
to the process and delivery of antidepressant treatment for 
these patients needs considerably more attention.
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